FDA grants a Type A meeting on December 18th to review new and expanded datasets submitted by Saol to help identify a feasible path forward without the need for an additional clinical trial ROSWELL, ...
Results reported for Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis. Company plans to meet with the FDA to determine path forward for efzofitimod in pulmonary sarcoidosis in the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback